Ikarian Capital, LLC Crispr Therapeutics Ag Put Options Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $25 Million - $46.7 Million	647,361 Added 31748.95%	649,400 $40.7 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $8.99 Million - $11.7 Million	-197,961 Reduced 98.98%	2,039 $92,000
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $8.69 Million - $13.6 Million	200,000 New	200,000 $11.2 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $13.8 Million - $22 Million	-197,300 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $297,540 - $422,927	-2,700 Reduced 1.35%	197,300 $22.1 Million
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $15.9 Million - $25.6 Million	158,100 Added 377.33%	200,000 $32.4 Million
Q1 2021 May 17, 2021	SELL	$110.72 - $210.04 $8.13 Million - $15.4 Million	-73,400 Reduced 63.66%	41,900 $5.11 Million
Q3 2020 Nov 16, 2020	SELL	$78.5 - $100.64 $5.01 Million - $6.42 Million	-63,800 Reduced 35.62%	115,300 $9.64 Million
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $1.87 Million - $3.46 Million	55,400 Added 44.79%	179,100 $7.6 Million
Q4 2019 Jan 31, 2020	BUY	$36.68 - $73.13 $4.54 Million - $9.05 Million	123,700 New	123,700 $7.53 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.